Given the present uncertainty, we need to wait and watch on how the tariff situation evolves. However, it is likely that in the event of the imposition of the tariff, Indian companies may contemplate ...

American pharmaceutical major Eli Lilly and Company on Thursday (March 20, 2025) launched its diabetes and obesity management drug Mounjaro (tirzepatide) in India. The company launched the drug in ...

India’s specialty chemicals sector is showing early signs of recovery in Q4 FY25, while pharmaceutical exports continue to grow at 8-9%, driven by strong demand for drugs like gRevlimid (blood ...

Brian Beers is a digital editor, writer, Emmy-nominated producer, and content expert with 15+ years of experience writing about corporate finance & accounting, fundamental analysis, and investing.

Mike Ryan, general manager of Europe and Asia Pacific at EVERSANA, spoke with Pharmaceutical Executive about the unique challenges market access challenges pharma companies face in Europe.

Innovations such as interactivity are making video more like the web in terms of delivering heightened results from marketing, including deeper engagement, ISI compliance and audience insights.

ProPublica is a nonprofit newsroom that investigates abuses of power. Sign up to receive our biggest stories as soon as they’re published. The Food and Drug Administration has found problems at ...

Today was supposed to mark the beginning of the end for cheaper, knockoff versions of hot weight-loss drugs. The Food and Drug Administration wants bulk production of the copycats to stop ...

It’s not just American companies rethinking their diversity, equity, and inclusion (DEI) initiatives. Swiss pharma giants Roche (RHHBY) and Novartis (NVS) are the latest companies to adjust ...

Purdue Pharma filed a new bankruptcy plan on Tuesday, a major step toward finalizing a proposed opioid settlement of at least $7.4 billion after a setback in the U.S. Supreme Court last year.

The information age has produced a generation of young people concerned about their health, but distrustful of big brands – and that includes the pharmaceutical industry. What are implications ...